Medical Condition News

RSS

New finding could help identify individuals with abnormal brain function

Mayo Clinic researchers found that the part of the brain generating seizures in individuals with epilepsy is functionally isolated from surrounding brain regions. The researchers hope this finding could be a clinical biomarker to help identify individuals with abnormal brain function.

9 Dec 2010

New report indicates that struggling economy may have reduced use of preventive care

A new report released by non-profit health care organization MN Community Measurement, indicates that the struggling economy may have reduced the use of preventive care, including breast cancer screenings and childhood immunizations, as well as the on-going care needed for chronic diseases like diabetes and vascular disease.

9 Dec 2010

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Patients treated by Welsh hospitals for upper gastrointestinal (GI) bleeding were 41% more likely to die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics.

9 Dec 2010

Results of proteomics study performed utilizing plasma samples from ADNI now available

The Foundation for the National Institutes of Health's Biomarkers Consortium announced today that the results of a proteomics study performed utilizing plasma samples from the Alzheimer's Disease Neuroimaging Initiative are ready to be shared with scientists worldwide for further analysis.

9 Dec 2010

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

New study shows how meditators don't ponder pain

Zen meditation has many health benefits, including a reduced sensitivity to pain. According to new research from the Universit- de Montr-al, meditators do feel pain but they simply don't dwell on it as much. These findings, published in the month's issue of Pain, may have implications for chronic pain sufferers, such as those with arthritis, back pain or cancer.

9 Dec 2010

Researchers discover central switch that regulates movement of cancer cells

Researchers at the University of Georgia have discovered a central switch that controls whether cells move or remain stationary. The misregulation of this switch may play a role in the increased movement of tumor cells and in the aggressiveness of tumors themselves.

9 Dec 2010

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

The management of children with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis has evolved significantly over the past decade. With a surge of pediatric research in the field, quality of life has become an important focus of study, as indicated by the number of related abstracts that will be presented at the 2010 Advances in Inflammatory Bowel Diseases, the Crohn's & Colitis Foundation's Clinical & Research Conference beginning tomorrow in Hollywood, Florida.

9 Dec 2010

Insulin related calls to poison centers increase 279%

Annual calls to poison centers regarding insulin have skyrocketed by 279 percent over the past 10 years, according to a new study authored by medical professionals at four U.S. poison centers.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Health2 Resources provides strategic research, analysis for ACCC project

The Association of Community Cancer Centers announced that results of a landmark study of how—and how well—the cancer patient's transition from the hospital inpatient setting to outpatient oncology group is managed. The study, designed to help hospitals and oncology groups improve their transition processes. The study was conducted by the Association of Community Cancer Centers, was conducted by ACCC, with strategic research and analysis provided by Health2 Resources.

9 Dec 2010

Systagenix launches new innovative website

Following the highly successful global launch of the new Corporate Identity, Systagenix has today unveiled its new innovative website - www.systagenix.com.

9 Dec 2010

Mortality is higher in for-profit than non-profit dialysis centers, says study

If you need dialysis for advanced kidney disease, where you get it could make a big difference. A large study found that patients in certain large chain facilities are significantly more likely to die than those treated elsewhere. Mortality was also higher in for-profit than non-profit dialysis centers.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Laparoscopic approach still best for most patients, not for all: Study

If skin is the body's fortress against germ invaders, shouldn't minimally invasive surgeries - operations guided by camera probes, conducted entirely within the abdomen - carry less risk for serious infection than procedures that slice the same cavity wide open?

9 Dec 2010

EULAR welcomes EPSCO Council's decision on tackling chronic diseases in Europe

The European League Against Rheumatism welcomes the outcomes of yesterday's Council of the European Union. In its meeting on 7 December, ministers for health adopted Council Conclusions on chronic diseases, in which the Council calls on Member States and the European Commission to adopt concrete, coordinated measures to tackle chronic diseases in Europe.

9 Dec 2010

Study demonstrates new test for early diagnosis of Turner syndrome

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) has demonstrated a novel and accurate test for early diagnosis of Turner syndrome. Turner syndrome affects one in 1,500 to 2,000 female live births and early diagnosis allows for the timely management of short stature and co-morbid conditions including cardiac and renal problems.

9 Dec 2010

Researchers to study effect of resveratrol on impaired IGT in older prediabetic patients

Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded $600,000 from the American Diabetes Association to study the effect of resveratrol, a chemical compound most notably found in red wine and grapes, on impaired glucose tolerance in older adults.

9 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

Medical Condition News

New finding could help identify individuals with abnormal brain function

New report indicates that struggling economy may have reduced use of preventive care

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Results of proteomics study performed utilizing plasma samples from ADNI now available

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

New study shows how meditators don't ponder pain

Researchers discover central switch that regulates movement of cancer cells

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

Insulin related calls to poison centers increase 279%

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Health2 Resources provides strategic research, analysis for ACCC project

Systagenix launches new innovative website

Mortality is higher in for-profit than non-profit dialysis centers, says study

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Laparoscopic approach still best for most patients, not for all: Study

EULAR welcomes EPSCO Council's decision on tackling chronic diseases in Europe

Study demonstrates new test for early diagnosis of Turner syndrome

Researchers to study effect of resveratrol on impaired IGT in older prediabetic patients

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News